ABSTRACT
Primary synovial osteochondromatosis (PSOC) is a rare but clinically significant cause of morbidity especially in the male population. Surgery is the primary treatment of choice, but the recurrence rate is reported to be high. Moreover, the presence of widespread loose bodies makes it a cumbersome procedure. The complete removal of the disease is tough at times and results in early recurrence. Radiosynovectomy is an established technique for treating various joint arthropathies. The role of radiosynovectomy in case of PSOC has not yet been explored. This case report described the case of a young male with PSOC of the knee joint who was treated with radiosynovectomy for pain relief. The patient reported complete relief from the pain along with significant improvement in joint mobility. The post-therapy three-phase bone scan also validated the reduction in joint inflammation. The patient was taken for surgical removal of the redundant loose bodies after a significant improvement in the pain and reduction in inflammation. Post-therapy radiation fibrosis of the synovium also helped in the en bloc removal of the disease. The role of radiosynovectomy in PSOC needs to be further explored concerning its potential role as an adjuvant to surgical procedures.
Subject(s)
Humans , Male , Chondromatosis, Synovial , Inflammation , Joints , Knee Joint , Knee , Radiation Pneumonitis , Recurrence , Synovial MembraneABSTRACT
RESUMEN La primera fase del ensayo clínico del anticuerpo monoclonal humanizado h-R3 (Nimotuzumab) marcado con 
, para la radioinmunoterapia de tumores cerebrales malignos fue ejecutada durante el período 2002-2005 en Cuba. El objetivo del trabajo fue analizar los datos de la vigilancia radiológica realizada durante el estudio, con respecto a las dosis estimadas inicialmente. Estas últimas se calcularon para cada nivel de actividad, operación y cantidad total de pacientes, considerando el decaimiento radiactivo del y que una misma persona realizaba todas las operaciones. Se demostró que el riesgo radiológico de la práctica es aceptable. Las hipótesis conservadoras empleadas para los cálculos y el cumplimiento de los procedimientos de seguridad establecidos, determinaron que la exposición medida fuera inferior a la estimada. La realización de este trabajo constituye una referencia para la introducción y desarrollo de la radioinmunoterapia en Cuba.
ABSTRACT The first phase of the clinical trial using the humanized monoclonal antibody h-R3 (Nimotuzumab) labelled with , for radioimmunotherapy of brain malignant was performed during the period 2002-2005 in Cuba. The aim of this work was to analyze data from the radiological surveillance of this research compared to initially estimated doses. These latter were calculated for each activity level, operation and total quantity of patients, considering the radioactive decay of and taking into account that only one person carries out all of the operations. It was demonstrated that the radiation risk of the practice is acceptable. The conservative hypotheses for dose assessment and the compliance with established safety procedures during this trial showed that the measured exposure was lower than that estimated. This paper is a reference useful to introduce and develop the RIT in Cuba.
ABSTRACT
AIM: To investigate the effect of 188Re labeled monoclonal antibody on prostatic specific membrane antigen 7E11C5.3,radioimmunotherapy for the treatment of human prostate cancer cell line LNCaP in vitro.METHODS: 188Re-7E11C5.3 was prepared by direct 2-mercaptoethanol reduction method.Labeling efficiency and radiochemical purity was measured by paper chromatography.Immunoreactive fraction was determined by linear extrapolation.Cytotoxicity to LNCaP cells was determined by MTT assay.RESULTS: The labeling yield of 188Re-7E11C5.3 was(93.16?2.18)%,the radiochemical purity was(95.62?0.48)%,and the immunoreactive fraction was(74.86?1.86)%.The inhibitory effect of 188Re-7E11C5.3 on cell proliferation of LNCaP cells was significantly higher than that of 188Re-mIgG or 188ReO-4.The 50% inhibitory doses(IC50) of 188Re-7E11C5.3,188Re-mIgG,and 188ReO-4 were(23.38?3.73)?107 Bq/L,(59.21?8.02)?107 Bq/L and(68.89?10.91)?107 Bq/L,respectively.CONCLUSION: 188Re-7E11C5.3 can effectively inhibit the growth of in vitro cultured prostate cancer cells and shows much potential for prostate cancer radioimmunotherapy.